Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis (Businesswire) - Jan 24, 2024 - "Endeavor expects to initiate Phase 2b study of ENV-101 for the treatment of IPF and progressive fibrosing-interstitial lung disease (PF-ILD) in 2024...Endeavor BioMedicines...announced successful completion of its Phase 2a clinical trial evaluating the company's lead investigational compound, ENV-101, in patients with idiopathic pulmonary fibrosis (IPF). ENV-101 is an oral small molecule inhibitor of the Hedgehog (Hh) signaling pathway that offers a novel approach to treating the underlying pathologic mechanisms that cause fibrotic lung diseases."
Enrollment closed • New P2b trial • Idiopathic Pulmonary Fibrosis • Immunology
|